RxDoctor Payments Data

Halla Moussa, MD

Internal Medicine · Kansas City, KSNPI 1063488526

Payments from drug & device makers

$1,480in general payments, 2019–2025

Across 43 payments — averaging $34.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$288
  • Novo Nordisk$239
  • Inari Medical, Inc.$177
  • MDD US Operations, LLC$125
  • AstraZeneca$111
  • Pfizer$97
  • plus $443 from 9 others

What the payments were for

  • Food & beverage$1,45398%
  • Education$272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,480 in reported general payments places this provider in the 80th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$71,722
Medicare patients
405
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$11,825
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,930
Memantine Hcl14$721
Potassium Chloride18$421
Losartan Potassium34$397
Albuterol Sulfate HfaAlbuterol Sulfate11$330
Gabapentin17$253
Atorvastatin Calcium56$233
Rosuvastatin Calcium22$218
Metoprolol Succinate21$192
Levothyroxine Sodium27$169
Montelukast Sodium11$169
Pantoprazole Sodium19$141
Sertraline Hcl17$137
Paroxetine Hcl11$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$90$11,82512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →